Triple Negative Breast cancer (TNBC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 

(Albany, US) DelveInsight has launched a new report on “Triple Negative Breast Cancer (TNBC) Market Insights, Epidemiology, and Market Forecast-2030“

DelveInsight’s “Triple Negative Breast Cancer (TNBC) Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Triple Negative Breast Cancer (TNBC), historical and forecasted epidemiology as well as the Triple Negative Breast Cancer (TNBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Triple Negative Breast facts:

  • Market Size of TNBC in the 7MM was found to be 438 Million in 2017.
  • As per breastcancer.org, about 70% of breast cancers diagnosed in people with an inherited BRCA mutation, particularly BRCA1, are triple-negative.
  • As per several secondary sources, it can be concluded that TNBCs are significantly larger and of higher grade, but less likely to have lymph node metastases than non-TNBCs.
  • Total Diagnosed Incident cases of Triple Negative Breast Cancer in the 7MM countries was 99,380 in 2017.
  • DelveInsight has also estimated the Sub-type specific cases of TNBC, which are ER-, PR- and HER2- .
  • In the United States, there were 4,793 cases of HER2-TNBC, followed by PR- and ER- sub-types.

Request for free Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

View Report: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

Scope of the Triple Negative Breast Report:

  • The report covers the descriptive overview of Triple Negative Breast Cancer (TNBC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Triple Negative Breast Cancer (TNBC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Triple Negative Breast Cancer (TNBC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Triple Negative Breast Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Triple Negative Breast Cancer (TNBC) market

Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

View Report: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

Triple Negative Breast Cancer is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

TNBC is characterized by various aggressive clinical pathologic features including onset at a younger age, higher mean tumor size, higher-grade tumors, and a higher rate of node positivity. Overall, TNBCs show an aggressive phenotype with a shorter time to relapse and metastatic disease than the more common hormone-receptorepositive invasive ductal carcinomas.

TNBC frequently metastasizes to the viscera, liver, lung or brain. However, this is not always the case as it may also have an oligometastatic phenotype closer to ER+ BC, with only lymph node and bone disease. TNBC is also heterogeneous in terms of time of recurrence. TNBC has a higher rate of recurrence in the first 5 years and a lower rate of recurrence afterwards. The pattern of late recurrence is generally associated with less aggressive disease, frequently with bone metastases.

Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

View Report: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

Some of the TNBC Companies:

  • Merck
  • Hoffmann-La Roche
  • Infinity Pharmaceuticals
  • CytoDyn
  • Treadwell Therapeutics
  • And Many Others

Triple Negative Breast Cancer Drugs Covered:

  • Pembrolizumab
  • Ipatasertib
  • IPI-549
  • Leronlimab (PRO 140)
  • CFI-400945
  • And Many Others

Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

View Report: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

Table of Contents:

  1. Key Insights
  2. Executive Summary of Triple Negative Breast Cancer (TNBC)
  3. Competitive Intelligence Analysis for Triple Negative Breast Cancer (TNBC)
  4. Triple Negative Breast Cancer (TNBC): Market Overview at a Glance
  1. Triple Negative Breast Cancer (TNBC): Disease Background and Overview
  2. Patient Journey
  3. Triple Negative Breast Cancer (TNBC) Epidemiology and Patient Population
  4. Treatment Algorithm, Current Treatment, and Medical Practices
  1. Unmet Needs
  2. Key Endpoints of Triple Negative Breast Cancer (TNBC) Treatment
  3. Marketed Products
  1. Emerging Therapies
  1. Triple Negative Breast Cancer (TNBC): Seven Major Market Analysis
  1. Attribute analysis
  2. 7MM: Market Outlook
  3. Access and Reimbursement Overview of Triple Negative Breast Cancer (TNBC)
  4. KOL Views
  5. Market Drivers
  6. Market Barriers

Request for detailed TOC: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

View Report: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

Cervical Intraepithelial Neoplasia Market and Epidemiology 2032 by DelveInsight

DelveInsight's " Cervical Intraepithelial Neoplasia Market Insights, Epidemiology, and Market Forecast-2032 " report delivers an in-depth understanding of Cervical Intraepithelial Neoplasia, historical and forecasted epidemiology as well as the Cervical Intraepithelial Neoplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Cervical Intraepithelial Neoplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cervical Intraepithelial Neoplasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Cervical Intraepithelial Neoplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cervical Intraepithelial Neoplasia market. Request for a Free Sample Report: Cervic...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more